Semler Scientific, Inc., Nasdaq-traded SMLR, announced that Joe Burnett was elected to be its new Director of Bitcoin Strategy. The company is one of the U.S. public companies that hold Bitcoin and has continued to add to its Bitcoin-based treasury strategy ever since it first began to do so in May 2024.
Eric Semler, company chairman, made a multi-year plan to accumulate 105,000 Bitcoins by December 2027. The company will purchase 10,000 Bitcoins by 2025 and expand to 42,000 by 2026 before reaching 105,000 by 2027. The funding will be through equity, debt financing, and cash flows generated by its business model operations.
Joe Burnett, who currently oversees Semler’s Bitcoin roadmap, approached with experience, having worked for some years at Unchained and Blockware Solutions. He has had financial experts ranging from Lyn Alden to Michael Saylor as hosts and is still one of the prominent voices in BTC markets and macroeconomics.
Bitcoin (BTC) declared a superior long-term monetary currency
His background includes leading market research and co-designing Blockware Marketplace, a leading U.S. Bitcoin mining platform. He further graduated with a master’s in business analytics in Georgia and started working in consulting with Ernst & Young.
Semler Scientific revealed a 287% Bitcoin gain and a $177 million holding profit in BTC by June 3, 2025. That track record and sound internal operations are a harbinger for aggressively building its BTC treasury.
He defined BTC as the superior long-term monetary currency and committed to constructing one of the world’s largest companies with BTC reserves. His accession reiterates the company’s traction towards a Bitcoin-standard treasury strategy.
Semler Scientific is still active in its medical division, where it markets FDA-approved QuantaFlo®, a product for diagnosing vascular conditions. The company looks for broader use clearance and continues to sell products that evaluate the patient risk of cardiac events.
Both with regard to digital assets and medical innovations, Semler Scientific aims to deliver consistent development to shareholders and remain one step ahead of the curve with regard to both financial and health markets.
